EC 2.7.12.1 - ATP:protein phosphotransferase (Ser/Thr- and Tyr- phosphorylating) (dual- specificity kinase)

3D structures of EC 2.7.12.1 - dual-specificity kinase in Protein Data Bank

updated: 6 January 2022, 2:15

1. 3nr9: Structure of Human Cdc2-like Kinase 2 (clk2)
2. 3kvw: Crystal Structure of Dual-specificity Tyrosine Phosphorylation Regulated Kinase 2 (dyrk2) in Complex with an Indirubin Ligand
3. 3k2l: Crystal Structure of Dual-specificity Tyrosine Phosphorylation Regulated Kinase 2 (dyrk2)
4. 3hmp: Crystal Structure of Human Mps1 Catalytic Domain in Complex with a Quinazolin Ligand Compound 4
5. 3hmo: Crystal Structure of Human Mps1 Catalytic Domain in Complex with The Inhibitor Staurosporine
6. 3hmn: Crystal Structure of Human Mps1 Catalytic Domain in Complex with Atp
7. 3h9f: Crystal Structure of Human Dual Specificity Protein Kinase (ttk) in Complex with a Pyrimido-diazepin Ligand
8. 3gfw: Crystal Structure of Human Dual Specificity Protein Kinase (ttk) in Complex with a Pyrolo-pyridin Ligand
9. 3dbq: Crystal Structure of Ttk Kinase Domain
10. 3cek: Crystal Structure of Human Dual Specificity Protein Kinase (ttk)
11. 6uwy: DYRK1A Bound to a Harmine Derivative
12. 3anr: Human DYRK1A/HARMINE Complex
13. 3anq: Human DYRK1A/INHIBITOR Complex
14. 2zmd: Crystal Structure of Human Mps1 Catalytic Domain T686A Mutant in Complex with Sp600125 Inhibitor
15. 2zmc: Crystal Structure of Human Mitotic Checkpoint Kinase Mps1 Catalytic Domain Apo Form
16. 2wu7: Crystal Structure of The Human Clk3 in Complex with V25
17. 2wu6: Crystal Structure of The Human Clk3 in Complex with Dki
18. 2wo6: Human Dual-specificity Tyrosine-phosphorylation-regulated Kinase 1a in Complex with a Consensus Substrate Peptide
19. 1z57: Crystal Structure of Human Clk1 in Complex with 10z- Hymenialdisine
20. 2vx3: Crystal Structure of The Human Dual Specificity Tyrosine- Phosphorylation-regulated Kinase 1a
21. 2vag: Crystal Structure of Di-phosphorylated Human Clk1 in Complex with a Novel Substituted Indole Inhibitor
22. 6ln1: A Natural Inhibitor of DYRK1A for Treatment of Diabetes Mellitus
23. 7ak3: Clk1 Bound with Caf052
24. 6zln: Clk1 Bound with GW807982X (cpd 8)
25. 6z2v: Clk3 A319V Mutant Bound with Beta-carboline Kh-carb13 (cpd 3)
26. 6yu1: Clk3 Bound with Beta-carboline Kh-carb13 (cpd 3)
27. 6yty: Clk3 A319V Mutant Bound with Benzothiazole Tg003 (cpd 2)
28. 6ytw: Clk3 Bound with Benzothiazole Tg003 (cpd 2)
29. 6yti: Clk1 Bound with Eth1610 (cpd 17)
30. 6ytg: Clk1 Bound with Beta-carboline Kh-carb13 (cpd 3)
31. 6yte: Clk1 Bound with Benzothiazole Tg003 (cpd 2)
32. 6ytd: Clk1 V324A Mutant Bound with Benzothiazole Tg003 (cpd 2)
33. 6yta: Clk1 Bound with Imidazopyridazine (cpd 1)
34. 6b4w: Ttk in Complex with Inhibitor
35. 6a1g: Crystal Structure of Human DYRK1A in Complex with Compound 32
36. 6a1f: Crystal Structure of Human DYRK1A in Complex with Compound 14
37. 5ztn: The Crystal Structure of Human Dyrk2 in Complex with Curcumin
38. 2eu9: Crystal Structure of Clk3
39. 2x9e: Human Mps1 in Complex with Nms-p715
40. 6z55: Crystal Structure of Clk3 in Complex with Macrocycle Ods2004070
41. 6z54: Crystal Structure of Clk3 in Complex with Macrocycle Ods2003178
42. 6z53: Crystal Structure of Clk3 in Complex with Macrocycle Ods2003128
43. 6z52: Crystal Structure of Clk3 in Complex with Macrocycle Ods2003136
44. 6z51: Crystal Structure of Clk3 in Complex with Macrocycle Ods2002941
45. 6z50: Crystal Structure of Clk1 in Complex with Macrocycle Ods2003208
46. 6z4z: Crystal Structure of Clk1 in Complex with Macrocycle Ods2004070
47. 6tnd: X-ray Structure of Mps1 in Complex with Compound 79
48. 6tnc: X-ray Structure of Mps1 in Complex with Compound 46
49. 6tnb: X-ray Structure of Mps1 in Complex with Compound 41
50. 6tn9: X-ray Structure of Mps1 in Complex with Compound 16
51. 6r8j: Crystal Structure of Di-phosphorylated Human Clk1 in Complex with 4- (1-methyl-1h-indol-3-yl)pyrimidin-2-amine
52. 6r6x: Crystal Structure of Di-phosphorylated Human Clk1 in Complex with 5- (1-methyl-1h-indol-3-yl)pyrimidin-4-amine
53. 6r6e: Crystal Structure of Di-phosphorylated Human Clk1 in Complex with 5- (6,7-dichloro-1-methyl-1h-indol-3-yl)pyrimidin-4-amine
54. 3raw: Crystal Structure of Human Cdc-like Kinase 3 Isoform in Complex with Leucettine L41
55. 6r3d: Crystal Structure of Di-phosphorylated Human Clk1 in Complex with 4- (6,7-dichloro-1h-indol-3-yl)pyrimidin-2-amine
56. 6qu2: Crystal Structure of DYRK1A Complexed with Fc162 Inhibitor
57. 6qty: Non-phosphorylated Human Clk1 in Complex with an Indole Inhibitor to 1.65 Ang
58. 6t6a: Crystal Structure of DYRK1A Complexed with Kufal319 (compound 11)
59. 6s1j: Crystal Structure of DYRK1A with Small Molecule Inhibitor
60. 6s1i: Crystal Structure of DYRK1A with Small Molecule Inhibitor
61. 6s1h: Crystal Structure of DYRK1A with Small Molecule Inhibitor
62. 6s1b: Crystal Structure of DYRK1A with Small Molecule Inhibitor
63. 6s17: Crystal Structure of DYRK1A with Small Molecule Inhibitor
64. 6s14: Crystal Structure of DYRK1A with Small Molecule Inhibitor
65. 6s11: Crystal Structure of DYRK1A with Small Molecule Inhibitor
66. 6rct: Crystal Structure of Clk3 in Complex with T3-clk
67. 6raa: Clk1 Kinase Domain with Bound Imidazopyridin Inhibitor Tp003
68. 6q8p: Structure of Clk1 with Bound N-methyl-10-nitropyrido[3,4-g]quinazolin- 2-amine
69. 6q8k: Clk1 with Bound Pyridoquinazoline
70. 6n6o: Crystal Structure of The Human Ttk in Complex with an Inhibitor
71. 3vqu: Crystal Structure of Human Mps1 Catalytic Domain in Complex with 4- [(4-amino-5-cyano-6-ethoxypyridin-2- Yl)amino]benzamide
72. 6uip: DYRK1A Kinase Domain in Complex with a 6-azaindole Derivative, Gnf2133.
73. 6khf: Crystal Structure of Clk3 in Complex with Cx-4945
74. 6khe: Crystal Structure of Clk2 in Complex with Cx-4945
75. 6khd: Crystal Structure of Clk1 in Complex with Cx-4945
76. 6k0j: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor
77. 4aze: Human DYRK1A in Complex with Leucettine L41
78. 6i5l: Crystal Structure of Clk1 in Complexed with Furo[3,2-b]pyridine Compound Vn316 (derivative of Compound 12h)
79. 6i5k: Crystal Structure of Clk1 in Complexed with Furo[3,2-b]pyridine Compound Vn345 (derivative of Compound 12h)
80. 6i5i: Crystal Structure of Clk1 in Complexed with Furo[3,2-b]pyridine Compound 12h
81. 6i5h: Crystal Structure of Clk1 in Complex with Furanopyrimidin Vn412
82. 4h7x: Crystal Structure of The Tetratricopeptide Repeat (tpr) Motif of Human Dual Specificity Protein Kinase Mps1
83. 4h7y: Crystal Structure of The Tetratricopeptide Repeat (tpr) Motif of Human Dual Specificity Protein Kinase Mps1
84. 6hdr: Human Dyrk2 Bound to Curcumin
85. 6hdp: Human Dyrk2 Bound to Scorzodihydrostilbene a
86. 6h3k: Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- D]pyrimidine Mps1 Inhibitors and Enables The Discovery of The Phase 1 Clinical Candidate Bos172722.
87. 6gvj: Human Mps1 Kinase Domain with Ordered Activation Loop
88. 4b94: Crystal Structure of Human Mps1 Tpr Domain
89. 6g33: Crystal Structure of Clk1 in Complex with 5-iodotubercidin
90. 4bhz: Scaffold Focused Virtual Screening: Prospective Application to The Discovery of Ttk Inhibitor
91. 4bi0: Scaffold Focused Virtual Screening: Prospective Application to The Discovery of Ttk Inhibitor
92. 4bi1: Scaffold Focused Virtual Screening: Prospective Application to The Discovery of Ttk Inhibitor
93. 4bi2: Scaffold Focused Virtual Screening: Prospective Application to The Discovery of Ttk Inhibitor
94. 6fyv: X-ray Structure of Clk4-kd(146-480)/cx-4945 at 2.46a
95. 6fyr: X-ray Structure of Clk3-kd(gp-[275-632], Non-phos.)/cpd-2 at 1.42a
96. 6fyp: X-ray Structure of Clk3-kd(gp-[275-632], Non-phos.)/cx-4945 at 2.29a
97. 6fyo: X-ray Structure of Clk1-kd(148-484)/cpd-2 at 2.32a
98. 6fyl: X-ray Structure of Clk2-kd(136-496)/cx-4945 at 1.95a
99. 6fyk: X-ray Structure of Clk2-kd(136-496)/indazole1 at 2.39a
100. 6fyi: X-ray Structure of Clk2-kd(130-496)/tg003 at 2.6a
101. 6ft9: Crystal Structure of Clk1 in Complex with Inhibitor 16
102. 6ft8: Crystal Structure of Clk1 in Complex with Inhibitor 8g
103. 6ft7: Crystal Structure of Clk3 in Complex with Compound 8a
104. 3w1f: Crystal Structure of Human Mps1 Catalytic Domain in Complex with 5-(5- Ethoxy-6-(1-methyl-1h-pyrazol-4-yl)-1h-indazol-3-yl)-2- Methylbenzenesulfonamide
105. 6ej4: DYRK1A in Complex with Xmd7-112
106. 6eiv: DYRK1A in Complex with Jwd-065
107. 6eis: DYRK1A in Complex with Jwc-055
108. 6eir: DYRK1A in Complex with Xmd15-27-2
109. 6eiq: DYRK1A in Complex with Xmd14-124
110. 6eip: DYRK1A in Complex with Xmd8-62e
111. 6eij: DYRK1A in Complex with Hg-8-60-1
112. 6eif: DYRK1A in Complex with Xmd7-117
113. 6tw2: Re-refined Crystal Structure of Di-phosphorylated Human Clk1 in Complex with a Novel Substituted Indole Inhibitor
114. 4c4e: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
115. 4c4f: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
116. 4c4g: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
117. 4c4h: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
118. 4c4i: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
119. 4c4j: Structure-based Design of Orally Bioavailable Pyrrolopyridine Inhibitors of The Mitotic Kinase Mps1
120. 4js8: Crystal Structure of Ttk Kinase Domain with an Inhibitor: 401348
121. 4jt3: Crystal Structure of Ttk Kinase Domain with an Inhibitor: 400740
122. 4mq1: The Crystal Structure of DYRK1A with a Bound Pyrido[2,3-d]pyrimidine Inhibitor
123. 4mq2: The Crystal Structure of DYRK1A with a Bound Pyrido[2,3-d]pyrimidine Inhibitor
124. 5y86: Crystal Structure of Kinase
125. 4pdp: Crystal Structure of Rad53 Kinase Domain and Scd2
126. 4pds: Crystal Structure of Rad53 Kinase Domain and Scd2 in Complex with Amppnp
127. 5xzw: Crystal Structure of Rad53 1-466
128. 5xzv: Crystal Structure of Rad53 1-466 in Complex with Amp-pnp
129. 5x8i: Crystal Structure of Human Clk1 in Complex with Compound 25
130. 5unp: Structure of Cdc2-like Kinase 2 (clk2) in Complex with Compound T-025 [n2-methyl-n4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7h-pyrrolo[2, 3-d]pyrimidine-2,4-diamine]
131. 5t2s: Structure of The Fha1 Domain of Rad53 Bound Simultaneously to The Brct Domain of Dbf4 and a Phosphopeptide.
132. 5t2f: Structure of The Fha1 Domain of Rad53 Bound to The Brct Domain of Dbf4
133. 5o91: Crystal Structure of Human Mps1 (ttk) C604W Mutant in Complex with Cpd-5
134. 5ntt: Crystal Structure of Human Mps1 (ttk) C604Y Mutant in Complex with Nms-p715
135. 5nad: Ttk Kinase Domain in Complex with Bay 1217389
136. 5na0: Ttk Kinase Domain in Complex with a Peg-linked Pyrimido-indolizine
137. 5n9s: Ttk Kinase Domain in Complex with Bay 1161909
138. 5n93: Ttk Kinase Domain in Complex with Tc-mps1-12
139. 5n87: Ttk Kinase Domain in Complex with Ntrc 0066-0
140. 5n84: Ttk Kinase Domain in Complex with MPS-BAY2B
141. 5n7v: Ttk Kinase Domain in Complex with Mpi-0479605
142. 5mrb: Crystal Structure of Human Mps1 (ttk) in Complex with Cpd-5
143. 5lxd: Crystal Structure of Dyrk2 in Complex with Eht 1610 (compound 2)
144. 5lxc: Crystal Structure of Dyrk2 in Complex with Eht 5372 (compound 1)
145. 5ljj: Crystal Structure of Human Mps1 (ttk) in Complex with Reversine
146. 5j1w: Crystal Structure of Human Clk1 in Complex with Pyrido[3,4- G]quinazoline Derivative Zw31 (compound 14)
147. 5j1v: Crystal Structure of Human Clk1 in Complex with Pyrido[3,4- G]quinazoline Derivative Zw29 (compound 13)
148. 5ei8: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
149. 5ei6: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
150. 5ei2: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
151. 5ehy: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
152. 5eho: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
153. 5ehl: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
154. 5eh0: Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (mps1) Using a Structure-based Hydridization Approach
155. 4o6l: Crystal Structure of Ttk Kinase Domain with an Inhibitor: 401498 (n- [(1r)-1-(2-chlorophenyl)propyl]-3-{4-[(1-methylpiperidin-4-yl) Oxy]phenyl}-1h-indazole-5-carboxamide)
156. 3wzj: Crystal Structure of Human Mps1 Catalytic Domain in Complex with 4-(6- (cyclohexylamino)-8-(((tetrahydro-2h-pyran-4-yl)methyl)amino) Imidazo[1,2-b]pyridazin-3-yl)-n-cyclopropylbenzamide
157. 3wzk: Crystal Structure of Human Mps1 Catalytic Domain in Complex with N- Cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3- Yl)benzamide
158. 5ap7: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
159. 5ap6: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
160. 5ap5: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
161. 5ap4: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
162. 5ap3: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
163. 5ap2: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
164. 5ap1: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
165. 5ap0: Naturally Occurring Mutations in The Mps1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
166. 5a54: DYRK1A in Complex with Nitro Benzothiazole Fragment
167. 5a4t: DYRK1A in Complex with Nitrile Benzothiazole Fragment
168. 5a4q: DYRK1A in Complex with Chloro Benzothiazole Fragment
169. 5a4l: DYRK1A in Complex with Fluoro Benzothiazole Fragment
170. 5a4e: DYRK1A in Complex with Methoxy Benzothiazole Fragment
171. 5a3x: DYRK1A in Complex with Hydroxy Benzothiazole Fragment
172. 4zeg: Crystal Structure of Ttk Kinase Domain in Complex with a Pyrazolopyrimidine Inhibitor
173. 4ylj: Crystal Structure of DYRK1A in Complex with 10-iodo-substituted 11h- Indolo[3,2-c]quinoline-6-carboxylic Acid Inhibitor 5j
174. 4ylk: Crystal Structure of DYRK1A in Complex with 10-chloro-substituted 11h- Indolo[3,2-c]quinolone-6-carboxylic Acid Inhibitor 5s
175. 4yll: Crystal Structure of DYRK1AA in Complex with 10-bromo-substituted 11h- Indolo[3,2-c]quinolone-6-carboxylic Acid Inhibitor 5t
176. 4yu2: Crystal Structure of DYRK1A with Harmine-derivatized Annh-75 Inhibitor
177. 4nct: Human DYRK1A in Complex with Pkc412
178. 3wyx: Crystal Structure of Human Mps1 Catalytic Domain in Complex with 6- ((3-(cyanomethoxy)-4-(1-methyl-1h-pyrazol-4-yl)phenyl)amino)-2- (cyclohexylamino)nicotinonitrile
179. 3wyy: Crystal Structure of Human Mps1 Catalytic Domain in Complex with (e)- 3-(4-((6-(((3s,5s,7s)-adamantan-1-yl)amino)-4-amino-5-cyanopyridin-2- Yl)amino)-2-(cyanomethoxy)phenyl)-n-(2-methoxyethyl)acrylamide
180. 4cv8: Mps1 Kinase with 3-aminopyridin-2-one Inhibitors
181. 4cv9: Mps1 Kinase with 3-aminopyridin-2-one Inhibitors
182. 4cva: Mps1 Kinase with 3-aminopyridin-2-one Inhibitors
183. 4d2s: Human Ttk in Complex with a DYRK1B Inhibitor
184. 6yf8: DYRK1A with Pst001
185. 7chm: Crystal Structure of Ttk Kinase Domain in Complex with Compound 8
186. 7chn: Crystal Structure of Ttk Kinase Domain in Complex with Compound 9
187. 7cht: Crystal Structure of Ttk Kinase Domain in Complex with Compound 30
188. 7cil: Crystal Structure of Ttk Kinase Domain in Complex with Compound 7
189. 7cja: Crystal Structure of Ttk Kinase Domain in Complex with Compound 28
190. 7clh: Crystal Structure of Ttk Kinase Domain in Complex with Compound 19
191. 7aj2: Structure of DYRK1A in Complex with Compound 3
192. 7aj4: Structure of DYRK1A in Complex with Compound 5
193. 7aj5: Structure of DYRK1A in Complex with Compound 10
194. 7aj7: Structure of DYRK1A in Complex with Compound 16
195. 7aj8: Structure of DYRK1A in Complex with Compound 25
196. 7aja: Structure of DYRK1A in Complex with Compound 28
197. 7ajm: Structure of DYRK1A in Complex with Compound 32
198. 7ajs: Structure of DYRK1A in Complex with Compound 33
199. 7ajv: Structure of DYRK1A in Complex with Compound 38
200. 7ajw: Structure of DYRK1A in Complex with Compound 46
201. 7ajy: Structure of DYRK1A in Complex with Compound 51
202. 7ak2: Structure of DYRK1A in Complex with Compound 53
203. 7aka: Structure of DYRK1A in Complex with Compound 54
204. 7akb: Structure of DYRK1A in Complex with Compound 56
205. 7ake: Structure of DYRK1A in Complex with Compound 58
206. 7akf: Structure of Dyrk2 in Complex with Compound 50
207. 7akh: Structure of Dyrk2 in Complex with Compound 58
208. 7akl: Structure of DYRK1A in Complex with Compound 50
209. 7a4o: Structure of DYRK1A in Complex with Ampnp
210. 7a4r: Structure of DYRK1A in Complex with Compound 1
211. 7a4s: Structure of DYRK1A in Complex with Compound 2
212. 7a4w: Structure of DYRK1A in Complex with Compound 3
213. 7a4z: Structure of DYRK1A in Complex with Compound 4
214. 7a51: Structure of DYRK1A in Complex with Compound 5
215. 7a52: Structure of DYRK1A in Complex with Compound 6
216. 7a53: Structure of DYRK1A in Complex with Compound 7
217. 7a55: Structure of DYRK1A in Complex with Compound 8
218. 7a5b: Structure of DYRK1A in Complex with Complex 10
219. 7a5d: Structure of DYRK1A in Complex with Compound 16
220. 7a5l: Tructure of DYRK1A in Complex with Compound 24
221. 7a5n: Structure of DYRK1A in Complex with Compound 34
222. 7opg: Crystal Structure of Clk1 in Complex with Compound 2 (cc513)
223. 7dg4: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 6
224. 7dh3: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 5
225. 7dh9: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 7
226. 7dhc: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 10
227. 7dhh: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 19
228. 7dhk: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 13
229. 7dhn: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 20
230. 7dho: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 14
231. 7dhv: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 8
232. 7djo: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 17
233. 7o7k: Crystal Structure of The Human DYRK1A Kinase Domain Bound to Abemaciclib
234. 7dl6: The Co-crystal Structure of Dyrk2 with a Small Molecule Inhibitor 18